4/12/2011

Covidien said it has finished enrolling 800 patients for a post-market study of its SilverHawk device, designed to clear plaque in the peripheral arteries. Covidien gained access to the atherectomy device after it acquired ev3 for $2.6 billion in July 2010.

Related Summaries